PURE Bioscience’s SDC Antimicrobial Effective Against T. mentagrophytes in Preclinical Tests

PURE Bioscience Grants Licenses to FTA Bioscience to Begin IND Process for Nail and Foot Fungus Products

SAN DIEGO (August 2, 2010) – PURE Bioscience (NASDAQ: PURE) today announced that based on encouraging preclinical data it has granted two product-specific licenses to pharmaceutical development partner FTA Bioscience for development of a silver dihydrogen citrate (SDC)-based treatment for tinea unguium, also referred to as onychomycosis (nail fungus), as well as for tinea pedis (athlete’s foot).

In a study directed by world-renown researcher Mahmoud A. Ghannoum, PhD, EMBA, PURE’s patented SDC was evaluated in the topical treatment of Trichophyton mentagrophytes dermatophytosis using the same guinea pig model previously developed and used in the preclinical evaluation of current FDA-approved antifungal agents for the treatment of onychomycosis.  Two groups of animals were infected with T. mentagrophytes; one group was treated with SDC twice daily for 7 days, and the other served as an untreated control.  The treatment group showed significant mycological and clinical improvement when compared with the control.  Dr. Ghannoum is the Chief Scientific Officer of FTA Bioscience and professor of Dermatology at University Hospital as well as Director for the Center for Medical Mycology and Co-Director of the Skin Diseases Research Center at Case Western Reserve University.

“Dermatophytes and Candida are major causes of superficial fungal infections of the feet which, if left untreated, can lead to progressive deterioration of the infected area that is often painful and can negatively impact the quality of life,” stated Anthony J. Balsamo Sr., M.D., F.A.C.S., Geisinger Specialty Clinics, Orthopedics and founder and CEO of FTA Bioscience.  “Current treatments are often ineffective for the approximately 35 million people with nail fungus and the 27 million people suffering from athlete’s foot in the United States.  We see a significant market opportunity to develop new SDC-based topical antifungal agents as an alternative to oral antifugals.  Oral medicines are not ideal because of their limited effectiveness, side effects and the potential drug interactions presented when used concurrently with other medicines.  Therefore, an effective topical treatment would be preferred and, furthermore, its continued use may help prevent recurrence of the infection.  We believe SDC could act not only as an effective cure but also as an effective preventative treatment.”

Dr. Ghannoum added, “We have observed exciting results from our preclinical work with SDC on various dermatophytes and Candida strains, including the T. mentagrophytes animal study.  We look forward to continuing our research to establish SDC as an effective antimicrobial agent for other dermatological conditions as well as for wound care, and we expect to file Investigational New Drug (IND) Applications for multiple products and indications in 2011.”

PURE Bioscience’s President and CEO, Michael L. Krall, said, “The team at FTA has invested significant time and resources into formulation development of SDC into topical fungal products, and we are certainly pleased with the results.  In our pharmaceutical partnering model, completion of a pre-defined preclinical proof-of-concept study is the final precursor to the issuance of any product specific license.  Therefore, upon review and acceptance of this proof-of-concept study by FTA, we promptly issued the license to FTA to proceed with the IND process.  We look forward to providing updates as clinical trials are completed and milestones are achieved.”

About FTA

Cleveland, Ohio-based FTA Bioscience, LLC (formerly FTA Therapeutics) focuses on development of clinical stage pharmaceutical products using advanced generation free-ion systems and surface applications for the prevention and treatment of infections caused by drug resistant microorganisms. Building on strategic partnerships with highly regarded academic institutions, FTA has established a solid platform for attaining its goal of moving products forward into and through clinical development.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  PURE is headquartered in El Cajon, California (San Diego metropolitan area).  Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.